Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

Rivoceranib

Rivoceranib Phase 2

Elevar Therapeutics · Phase 2 · Terminated · Enrollment 80

NCT04119453

ArmPopulationDoseEstimandComparatorEfficacy
Rivoceranib 700 mgR/M ACC (n = 80; 72 evaluable)700 mgSingle armn/robjective response rate (investigator): 15.3%, primary analysisobjective response rate (independent review): 9.7%, primary analysismedian progression-free survival: 9 months, primary analysismedian duration of response (investigator): 14.9 months, primary analysis